Cover Image
市場調查報告書

亞太地區的癲癇治療藥市場

Epilepsy Therapeutics Market in the APAC Region 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 322239
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的癲癇治療藥市場 Epilepsy Therapeutics Market in the APAC Region 2015-2019
出版日期: 2014年12月31日 內容資訊: 英文 86 Pages
簡介

亞太地區的癲癇治療藥市場,從2014年到2019年之間,預計以5.78%的CAGR(年複合成長率)擴大。2014年的亞太地區癲癇治療藥市場上,日本佔了主導的佔有率,不過,今後的市場上,印度和中國達成急速成長的可能性變高。

本報告提供亞太地區癲癇治療藥現況與今後的預測,各地區的市場規模和未來預測,市場成長因素與課題,並提供主要企業簡介等資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 罹患率和盛行率

  • 全球
  • 中國
  • 日本

第7章 對癲癇的NIH支出

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各藥物世代的市場區隔

第10章 全球癲癇治療藥市場

  • 亞太地區癲癇治療藥的成長率預測
  • 日本的癲癇治療藥市場
  • 澳洲的癲癇治療藥市場
  • 中國的癲癇治療藥市場
  • 印度的癲癇治療藥市場

第11章 主要國家

  • 日本
  • 澳洲
  • 中國
  • 印度

第12章 購買標準

第13章 市場成長因素

第14章 成長因素與其影響

第15章 市場課題

第16章 成長因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • GlaxoSmithKline
    • Eisai
    • UCB
    • Pfizer
  • Other and Future 有力供應商

第20章 主要供應商分析

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

第21章 相關報告

目錄
Product Code: IRTNTR4895

About Epilepsy Therapeutics

Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.

TechNavio's analysts forecast the Epilepsy Therapeutics market in the APAC to grow at a CAGR of 5.78 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Epilepsy Therapeutics market in the APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs used for the treatment of the symptoms of epilepsy in APAC.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market in the region. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Epilepsy Therapeutics Market in the APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Countries

  • Australia
  • China
  • India
  • Japan

Key Vendors

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

Other Prominent Vendors

  • Abbvie
  • Acorda Therapeutics
  • Dainippon Sumitomo Pharma
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Janssen Pharmaceuticals
  • Marinus Pharmaceuticals
  • Meda AB
  • Novartis
  • Sage Therapeutics
  • Shire
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Upsher-Smith Laboratories
  • Valeant Pharmaceuticals

Market Driver

  • Unmet Medical Need
  • For a full, detailed list, view our report

Market Challenge

  • Generic Erosion
  • For a full, detailed list, view our report

Market Trend

  • Reformulation of Marketed Drugs
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1 Market Overview
  • 03.2 Product Offerings

04. Market Research Methodology

  • 04.1 Market Research Process
  • 04.2 Research Methodology

05. Introduction

06. Incidence and Prevalence

  • 06.1 Global
  • 06.2 China
  • 06.3 Japan

07. NIH Funding for Epilepsy

08. Market Lancape

  • 08.1 Market Overview
  • 08.2 Market Size and Forecast
  • 08.3 Five Forces Analysis

09. Market Segmentation by Generation of Drugs

10. Country-wise Segmentation

  • 10.1 Country-wise YoY Growth Rate of Epilepsy Therapeutics market in APAC 2014-2019
  • 10.2 Epilepsy Market in Japan
  • 10.3 Epilepsy Market in Australia
  • 10.4 Epilepsy Market in China
  • 10.5 Epilepsy Market in India

11. Key Leading Countries

  • 11.1 Japan
  • 11.2 Australia
  • 11.3 China
  • 11.4 India

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Tren

18. Tren and their Impact

19. Vendor Lancape

  • 19.1 Competitive Scenario
    • 19.1.1 Key News
    • 19.1.2 Mergers and Acquisitions
  • 19.2 Market Share Analysis 2014
    • 19.2.1 GlaxoSmithKline
    • 19.2.2 Eisai
    • 19.2.3 UCB
    • 19.2.4 Pfizer
  • 19.3 Other and Future Prominent Vendors

20. Key Vendor Analysis

  • 20.1 Eisai
    • 20.1.1 Key Facts
    • 20.1.2 Business Overview
    • 20.1.3 Product Segmentation by Revenue 2013
    • 20.1.4 Product Segmentation by Revenue 2012 and 2013
    • 20.1.5 Geographical Segmentation by Revenue 2013
    • 20.1.6 Business Strategy
    • 20.1.7 Recent Developments
    • 20.1.8 SWOT Analysis
  • 20.2 GlaxoSmithKline
    • 20.2.1 Key Facts
    • 20.2.2 Business Overview
    • 20.2.3 Business Segmentation
    • 20.2.4 Business Segmentation by Revenue 2012 and 2013
    • 20.2.5 Sales by Geography
    • 20.2.6 Pipeline Products
    • 20.2.7 Business Strategy
    • 20.2.8 Key Information
    • 20.2.9 SWOT Analysis
  • 20.3 Pfizer
    • 20.3.1 Key Facts
    • 20.3.2 Business Overview
    • 20.3.3 Business Segmentation by Revenue 2013
    • 20.3.4 Business Segmentation by Revenue 2012 and 2013
    • 20.3.5 Geographical Segmentation by Revenue
    • 20.3.6 Business Strategy
    • 20.3.7 Key Developments
    • 20.3.8 SWOT Analysis
  • 20.4 UCB
    • 20.4.1 Key Facts
    • 20.4.2 Business Overview
    • 20.4.3 Product Segmentation by Revenue 2013
    • 20.4.4 Product Segmentation by Revenue 2012 and 2013
    • 20.4.5 Geographical Segmentation by Revenue 2013
    • 20.4.6 Business Strategy
    • 20.4.7 Recent Developments
    • 20.4.8 SWOT Analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Incidence and Prevalence of Epilepsy by WHO
  • Exhibit 3: Treatment Statistics for Epilepsy
  • Exhibit 4: Prevalence of Epilepsy in China
  • Exhibit 5: NIH Funding for Epilepsy (US$ million) FY2011-FY2015
  • Exhibit 6: Epilepsy Therapeutics market in APAC 2014-2019 (US$ million)
  • Exhibit 7: Epilepsy Therapeutics Market in APAC Segmentation by Generation of Drugs
  • Exhibit 8: Market Share of APAC in Global Epilepsy Market
  • Exhibit 9: Epilepsy Therapeutics Market in APAC by Country 2014
  • Exhibit 10: Epilepsy Therapeutics market in APAC by Country 2019
  • Exhibit 11: Epilepsy Therapeutics Market in APAC 2014-2019 (US$ million)
  • Exhibit 12: Epilepsy Therapeutics Market in APAC 2014-2019
  • Exhibit 13: Epilepsy Market in Japan 2014-2019 (US$ million)
  • Exhibit 14: Epilepsy Market in Australia 2014-2019 (US$ million)
  • Exhibit 15: Epilepsy Market in China 2014-2019 (US$ million)
  • Exhibit 16: Epilepsy Market in India 2014-2019 (US$ million)
  • Exhibit 17: Key Leading Countries in the Epilepsy Therapeutics market in APAC 2014
  • Exhibit 18: Impact of Loss of Exclusivity for Lyrica in Canadian market (US$ million)
  • Exhibit 19: GlaxoSmithKline: Anti-epileptic Drug Portfolio in APAC
  • Exhibit 20: Lamictal Revenue 2011-2014 (US$ million)
  • Exhibit 21: Lamictal Sales Segmentation by Geography 2014
  • Exhibit 22: Eisai: Anti-epileptic Drug Portfolio in APAC
  • Exhibit 23: Fycompa: Pipeline Status
  • Exhibit 24: Inovelon: Pipeline Status
  • Exhibit 25: UCB: Anti-epileptic Drug Portfolio in APAC
  • Exhibit 26: Keppra Sales 2010-2014 (US$ million)
  • Exhibit 27: Keppra Sales by Geography 2014
  • Exhibit 28: Vimpat Sales by 2009-2014 (US$ million)
  • Exhibit 29: Vimpat Sales by Geography 2014
  • Exhibit 30: Vimpat: Pipeline Status
  • Exhibit 31: Lyrica Revenue 2011-2014 (US$ million)
  • Exhibit 32: Lyrica Revenue by Geography 2014
  • Exhibit 33: Eisai: Product Segmentation by Revenue 2014
  • Exhibit 34: Eisai: Product Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 35: Eisai: Geographical Segmentation by Revenue 2014
  • Exhibit 36: GlaxoSmithKline: Business Segmentation 2014
  • Exhibit 37: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 (US$ billion)
  • Exhibit 38: GlaxoSmithKline: Sales by Geography 2014
  • Exhibit 39: GlaxoSmithKline: Pipeline Products 2014
  • Exhibit 40: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 41: Pfizer: Business Segmentation by Revenue 2013 and 2014
  • Exhibit 42: Pfizer: Geographical Segmentation by Revenue 2014
  • Exhibit 43: UCB: Product Segmentation by Revenue 2014
  • Exhibit 44: UCB: Product Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 45: UCB: Geographical Segmentation by Revenue 2014
Back to Top